Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-02-28

AUTHORS

Benjamin Turner, Bruce A. C. Cree, Ludwig Kappos, Xavier Montalban, Caroline Papeix, Jerry S. Wolinsky, Regine Buffels, Damian Fiore, Hideki Garren, Jian Han, Stephen L. Hauser

ABSTRACT

OBJECTIVE: The efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I (NCT01247324) and OPERA II (NCT01412333) phase III studies has been reported; here we present subgroup analyses of efficacy endpoints from the pooled OPERA I and OPERA II populations. METHODS: Patients with RMS were randomized to either ocrelizumab 600 mg administered by intravenous infusion every 24 weeks or subcutaneous IFN β-1a 44 µg three times per week throughout the 96-week treatment period. Relapse, disability, and MRI outcomes were analyzed for predefined and post hoc subgroups based on demographic and disease characteristics along with prior treatment using appropriate statistical tests to determine the treatment effect in subgroups and treatment-by-subgroup interactions. RESULTS: The significant treatment benefit of ocrelizumab, versus IFN β-1a, observed in the overall OPERA I and OPERA II pooled populations was maintained across most subgroup strata for all endpoints, including annualized relapse rate, disability progression, and MRI outputs. CONCLUSIONS: The treatment effect of ocrelizumab versus IFN β-1a, measured by clinical and MRI outcomes, was maintained across most of the subgroups and strata of interest, and the pattern of treatment benefit across all subgroups was consistent with that from the pooled OPERA studies. More... »

PAGES

1-12

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00415-019-09248-6

DOI

http://dx.doi.org/10.1007/s00415-019-09248-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112463940

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30820738


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Royal London Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416041.6", 
          "name": [
            "Department of Neurology, The Royal London Hospital, E1 1BB, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Turner", 
        "givenName": "Benjamin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, San Francisco", 
          "id": "https://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cree", 
        "givenName": "Bruce A. C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University Hospital Basel, University of Basel, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kappos", 
        "givenName": "Ludwig", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Toronto", 
          "id": "https://www.grid.ac/institutes/grid.17063.33", 
          "name": [
            "Vall d\u2019Hebron University Hospital, Barcelona, Spain", 
            "Division of Neurology, St Michael\u2019s Hospital, University of Toronto, Toronto, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Montalban", 
        "givenName": "Xavier", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Piti\u00e9-Salp\u00eatri\u00e8re Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411439.a", 
          "name": [
            "Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Papeix", 
        "givenName": "Caroline", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas Health Science Center at Houston", 
          "id": "https://www.grid.ac/institutes/grid.267308.8", 
          "name": [
            "McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wolinsky", 
        "givenName": "Jerry S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "F. Hoffmann-La Roche Ltd, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Buffels", 
        "givenName": "Regine", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fiore", 
        "givenName": "Damian", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garren", 
        "givenName": "Hideki", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Han", 
        "givenName": "Jian", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, San Francisco", 
          "id": "https://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hauser", 
        "givenName": "Stephen L.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00415-009-0093-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008572105", 
          "https://doi.org/10.1007/s00415-009-0093-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00415-009-0093-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008572105", 
          "https://doi.org/10.1007/s00415-009-0093-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00415-009-0093-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008572105", 
          "https://doi.org/10.1007/s00415-009-0093-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1601277", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010407214"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00415-013-6968-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011679983", 
          "https://doi.org/10.1007/s00415-013-6968-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(12)70056-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023523128"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)61768-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028198660"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13760-014-0308-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029503684", 
          "https://doi.org/10.1007/s13760-014-0308-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.msard.2016.05.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029842590"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458511421054", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030336804"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458511421054", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030336804"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458511421054", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030336804"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(11)70023-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042611746"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.msard.2015.04.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043695250"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00415-013-6954-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051236120", 
          "https://doi.org/10.1007/s00415-013-6954-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512450354", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051838944"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512450354", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051838944"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512450354", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051838944"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ana.22366", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052372006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/01.wnl.0000194259.90286.fe", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064347771"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/01.wnl.0000194259.90286.fe", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064347771"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/01.wnl.0000194259.90286.fe", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064347771"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/01.wnl.0000194259.90286.fe", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064347771"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-02-28", 
    "datePublishedReg": "2019-02-28", 
    "description": "OBJECTIVE: The efficacy and safety of ocrelizumab, versus interferon (IFN) \u03b2-1a, for the treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I (NCT01247324) and OPERA II (NCT01412333) phase III studies has been reported; here we present subgroup analyses of efficacy endpoints from the pooled OPERA I and OPERA II populations.\nMETHODS: Patients with RMS were randomized to either ocrelizumab 600\u00a0mg administered by intravenous infusion every 24\u00a0weeks or subcutaneous IFN \u03b2-1a 44\u00a0\u00b5g three times per week throughout the 96-week treatment period. Relapse, disability, and MRI outcomes were analyzed for predefined and post hoc subgroups based on demographic and disease characteristics along with prior treatment using appropriate statistical tests to determine the treatment effect in subgroups and treatment-by-subgroup interactions.\nRESULTS: The significant treatment benefit of ocrelizumab, versus IFN \u03b2-1a, observed in the overall OPERA I and OPERA II pooled populations was maintained across most subgroup strata for all endpoints, including annualized relapse rate, disability progression, and MRI outputs.\nCONCLUSIONS: The treatment effect of ocrelizumab versus IFN \u03b2-1a, measured by clinical and MRI outcomes, was maintained across most of the subgroups and strata of interest, and the pattern of treatment benefit across all subgroups was consistent with that from the pooled OPERA studies.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00415-019-09248-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1014525", 
        "issn": [
          "0340-5354", 
          "1432-1459"
        ], 
        "name": "Journal of Neurology", 
        "type": "Periodical"
      }
    ], 
    "name": "Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis", 
    "pagination": "1-12", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c80419aa1516cd161b3f5d10f43be8a173a089c9d195d43e53bb1b778a1341e8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30820738"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0423161"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00415-019-09248-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112463940"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00415-019-09248-6", 
      "https://app.dimensions.ai/details/publication/pub.1112463940"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000349_0000000349/records_113647_00000005.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00415-019-09248-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00415-019-09248-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00415-019-09248-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00415-019-09248-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00415-019-09248-6'


 

This table displays all metadata directly associated to this object as RDF triples.

189 TRIPLES      21 PREDICATES      40 URIs      18 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00415-019-09248-6 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nd26f6112ce6e4e6eb2f9d79a046c05bd
4 schema:citation sg:pub.10.1007/s00415-009-0093-1
5 sg:pub.10.1007/s00415-013-6954-7
6 sg:pub.10.1007/s00415-013-6968-1
7 sg:pub.10.1007/s13760-014-0308-9
8 https://doi.org/10.1002/ana.22366
9 https://doi.org/10.1016/j.msard.2015.04.006
10 https://doi.org/10.1016/j.msard.2016.05.015
11 https://doi.org/10.1016/s0140-6736(12)61768-1
12 https://doi.org/10.1016/s1474-4422(11)70023-0
13 https://doi.org/10.1016/s1474-4422(12)70056-x
14 https://doi.org/10.1056/nejmoa1601277
15 https://doi.org/10.1177/1352458511421054
16 https://doi.org/10.1177/1352458512450354
17 https://doi.org/10.1212/01.wnl.0000194259.90286.fe
18 schema:datePublished 2019-02-28
19 schema:datePublishedReg 2019-02-28
20 schema:description OBJECTIVE: The efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I (NCT01247324) and OPERA II (NCT01412333) phase III studies has been reported; here we present subgroup analyses of efficacy endpoints from the pooled OPERA I and OPERA II populations. METHODS: Patients with RMS were randomized to either ocrelizumab 600 mg administered by intravenous infusion every 24 weeks or subcutaneous IFN β-1a 44 µg three times per week throughout the 96-week treatment period. Relapse, disability, and MRI outcomes were analyzed for predefined and post hoc subgroups based on demographic and disease characteristics along with prior treatment using appropriate statistical tests to determine the treatment effect in subgroups and treatment-by-subgroup interactions. RESULTS: The significant treatment benefit of ocrelizumab, versus IFN β-1a, observed in the overall OPERA I and OPERA II pooled populations was maintained across most subgroup strata for all endpoints, including annualized relapse rate, disability progression, and MRI outputs. CONCLUSIONS: The treatment effect of ocrelizumab versus IFN β-1a, measured by clinical and MRI outcomes, was maintained across most of the subgroups and strata of interest, and the pattern of treatment benefit across all subgroups was consistent with that from the pooled OPERA studies.
21 schema:genre research_article
22 schema:inLanguage en
23 schema:isAccessibleForFree false
24 schema:isPartOf sg:journal.1014525
25 schema:name Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
26 schema:pagination 1-12
27 schema:productId N0ebcdce82abb46a6a1326ebaf85e2bbc
28 N67083d4ac20b4b4e817fd6e220f9b1bc
29 N8f37ca5f3a844821afd65af0beaf753a
30 N98be66b6ea6e419dac4204f7b50d179c
31 Nec801acb4dc74a9eb009cb97a8fbcae0
32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112463940
33 https://doi.org/10.1007/s00415-019-09248-6
34 schema:sdDatePublished 2019-04-11T10:31
35 schema:sdLicense https://scigraph.springernature.com/explorer/license/
36 schema:sdPublisher N0377badfdbff441bb43fa03b025a55d3
37 schema:url https://link.springer.com/10.1007%2Fs00415-019-09248-6
38 sgo:license sg:explorer/license/
39 sgo:sdDataset articles
40 rdf:type schema:ScholarlyArticle
41 N00c12de2f9c04bdfb53c776a05ca2256 schema:affiliation https://www.grid.ac/institutes/grid.416041.6
42 schema:familyName Turner
43 schema:givenName Benjamin
44 rdf:type schema:Person
45 N0377badfdbff441bb43fa03b025a55d3 schema:name Springer Nature - SN SciGraph project
46 rdf:type schema:Organization
47 N0ebcdce82abb46a6a1326ebaf85e2bbc schema:name nlm_unique_id
48 schema:value 0423161
49 rdf:type schema:PropertyValue
50 N12f254d26d1b4d069517705416c1a264 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
51 schema:familyName Hauser
52 schema:givenName Stephen L.
53 rdf:type schema:Person
54 N25b10860b8d54970bf098d7ee04740e1 rdf:first N681cc3e82f1248929e5940ad2c41af45
55 rdf:rest Nc385303c28354447b50f3233d8e471fe
56 N288c853a14d14e43b1d7175a0b22830d rdf:first N3db5b8804eb241ac994039046080db24
57 rdf:rest N30fce049b17b41b090efc092fe1b1144
58 N30fce049b17b41b090efc092fe1b1144 rdf:first N99f41b9e95b64c1faf3ffd9af4364eaf
59 rdf:rest Nbed081a7bc9541cfb7f978c0ea5a756e
60 N35b56cf630714643afa112e2beef4195 schema:name University Hospital Basel, University of Basel, Basel, Switzerland
61 rdf:type schema:Organization
62 N3db5b8804eb241ac994039046080db24 schema:affiliation N35b56cf630714643afa112e2beef4195
63 schema:familyName Kappos
64 schema:givenName Ludwig
65 rdf:type schema:Person
66 N56c311bf02584ee0abd5506a52f49b68 rdf:first N9208eae991814a2c83e1fa61bb3468e3
67 rdf:rest N288c853a14d14e43b1d7175a0b22830d
68 N61f6eab5089c4d239717012ffce24aab rdf:first N12f254d26d1b4d069517705416c1a264
69 rdf:rest rdf:nil
70 N67083d4ac20b4b4e817fd6e220f9b1bc schema:name readcube_id
71 schema:value c80419aa1516cd161b3f5d10f43be8a173a089c9d195d43e53bb1b778a1341e8
72 rdf:type schema:PropertyValue
73 N673920d8b33a4e098b4d371ee74a6e42 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
74 schema:familyName Han
75 schema:givenName Jian
76 rdf:type schema:Person
77 N681cc3e82f1248929e5940ad2c41af45 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
78 schema:familyName Fiore
79 schema:givenName Damian
80 rdf:type schema:Person
81 N6ea41b27ef514231858796caf4e7bcff schema:affiliation https://www.grid.ac/institutes/grid.411439.a
82 schema:familyName Papeix
83 schema:givenName Caroline
84 rdf:type schema:Person
85 N8f37ca5f3a844821afd65af0beaf753a schema:name pubmed_id
86 schema:value 30820738
87 rdf:type schema:PropertyValue
88 N9208eae991814a2c83e1fa61bb3468e3 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
89 schema:familyName Cree
90 schema:givenName Bruce A. C.
91 rdf:type schema:Person
92 N98be66b6ea6e419dac4204f7b50d179c schema:name doi
93 schema:value 10.1007/s00415-019-09248-6
94 rdf:type schema:PropertyValue
95 N99f41b9e95b64c1faf3ffd9af4364eaf schema:affiliation https://www.grid.ac/institutes/grid.17063.33
96 schema:familyName Montalban
97 schema:givenName Xavier
98 rdf:type schema:Person
99 N9b2d34d88024441c885b400d6a0f1b72 rdf:first Ndba69344644f4ed29080d817e5e57849
100 rdf:rest N25b10860b8d54970bf098d7ee04740e1
101 Nbb9e670e83ca4a879b8de78549ad3379 schema:affiliation https://www.grid.ac/institutes/grid.267308.8
102 schema:familyName Wolinsky
103 schema:givenName Jerry S.
104 rdf:type schema:Person
105 Nbed081a7bc9541cfb7f978c0ea5a756e rdf:first N6ea41b27ef514231858796caf4e7bcff
106 rdf:rest Nd10e45ff3dfc4a509131c959cf82f03c
107 Nc385303c28354447b50f3233d8e471fe rdf:first Nc96916345be6413499fd75c45ad91c8d
108 rdf:rest Nfde8ae6518e04c048f0c67f3cfc1dd4e
109 Nc96916345be6413499fd75c45ad91c8d schema:affiliation https://www.grid.ac/institutes/grid.418158.1
110 schema:familyName Garren
111 schema:givenName Hideki
112 rdf:type schema:Person
113 Nd10e45ff3dfc4a509131c959cf82f03c rdf:first Nbb9e670e83ca4a879b8de78549ad3379
114 rdf:rest N9b2d34d88024441c885b400d6a0f1b72
115 Nd26f6112ce6e4e6eb2f9d79a046c05bd rdf:first N00c12de2f9c04bdfb53c776a05ca2256
116 rdf:rest N56c311bf02584ee0abd5506a52f49b68
117 Ndba69344644f4ed29080d817e5e57849 schema:affiliation https://www.grid.ac/institutes/grid.417570.0
118 schema:familyName Buffels
119 schema:givenName Regine
120 rdf:type schema:Person
121 Nec801acb4dc74a9eb009cb97a8fbcae0 schema:name dimensions_id
122 schema:value pub.1112463940
123 rdf:type schema:PropertyValue
124 Nfde8ae6518e04c048f0c67f3cfc1dd4e rdf:first N673920d8b33a4e098b4d371ee74a6e42
125 rdf:rest N61f6eab5089c4d239717012ffce24aab
126 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
127 schema:name Medical and Health Sciences
128 rdf:type schema:DefinedTerm
129 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
130 schema:name Clinical Sciences
131 rdf:type schema:DefinedTerm
132 sg:journal.1014525 schema:issn 0340-5354
133 1432-1459
134 schema:name Journal of Neurology
135 rdf:type schema:Periodical
136 sg:pub.10.1007/s00415-009-0093-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008572105
137 https://doi.org/10.1007/s00415-009-0093-1
138 rdf:type schema:CreativeWork
139 sg:pub.10.1007/s00415-013-6954-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051236120
140 https://doi.org/10.1007/s00415-013-6954-7
141 rdf:type schema:CreativeWork
142 sg:pub.10.1007/s00415-013-6968-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011679983
143 https://doi.org/10.1007/s00415-013-6968-1
144 rdf:type schema:CreativeWork
145 sg:pub.10.1007/s13760-014-0308-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029503684
146 https://doi.org/10.1007/s13760-014-0308-9
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1002/ana.22366 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052372006
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1016/j.msard.2015.04.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043695250
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1016/j.msard.2016.05.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029842590
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1016/s0140-6736(12)61768-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028198660
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1016/s1474-4422(11)70023-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042611746
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1016/s1474-4422(12)70056-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1023523128
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1056/nejmoa1601277 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010407214
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1177/1352458511421054 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030336804
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1177/1352458512450354 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051838944
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1212/01.wnl.0000194259.90286.fe schema:sameAs https://app.dimensions.ai/details/publication/pub.1064347771
167 rdf:type schema:CreativeWork
168 https://www.grid.ac/institutes/grid.17063.33 schema:alternateName University of Toronto
169 schema:name Division of Neurology, St Michael’s Hospital, University of Toronto, Toronto, Canada
170 Vall d’Hebron University Hospital, Barcelona, Spain
171 rdf:type schema:Organization
172 https://www.grid.ac/institutes/grid.266102.1 schema:alternateName University of California, San Francisco
173 schema:name Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
174 rdf:type schema:Organization
175 https://www.grid.ac/institutes/grid.267308.8 schema:alternateName The University of Texas Health Science Center at Houston
176 schema:name McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA
177 rdf:type schema:Organization
178 https://www.grid.ac/institutes/grid.411439.a schema:alternateName Pitié-Salpêtrière Hospital
179 schema:name Pitié-Salpêtrière Hospital, Paris, France
180 rdf:type schema:Organization
181 https://www.grid.ac/institutes/grid.416041.6 schema:alternateName Royal London Hospital
182 schema:name Department of Neurology, The Royal London Hospital, E1 1BB, London, UK
183 rdf:type schema:Organization
184 https://www.grid.ac/institutes/grid.417570.0 schema:alternateName Roche (Switzerland)
185 schema:name F. Hoffmann-La Roche Ltd, Basel, Switzerland
186 rdf:type schema:Organization
187 https://www.grid.ac/institutes/grid.418158.1 schema:alternateName Roche (United States)
188 schema:name Genentech, Inc., South San Francisco, CA, USA
189 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...